促排卵中人绒毛膜促性腺激素扳机时机与药物选择

doi:10.7504/fk2014120105

摘要/Abstract

摘要：

人绒毛膜促性腺激素（HCG）扳机目的在于促进卵母细胞最后成熟与排卵，此为促排卵中的关键点之一，并与治疗结局密切相关。促排卵周期中HCG的扳机时机主要依赖于对卵泡径线、血中雌孕激素水平和子宫内膜情况等进行综合分析、判断来确定。HCG扳机的药物有HCG制剂和促性腺激素释放激素激动剂（GnRH-a）两种，针对患者和促排卵方案合理选择不同的药物扳机排卵，其对改善助孕结局和降低促排卵并发症有益。

关键词: 促排卵, 人绒毛膜促性腺激素, 扳机时机

Abstract:

Abstract:HCG trigger is important for inducing oocyte maturation and ovulation induction, which has also been thought one of the key points of ovulation induction and is closely related to the outcomes of ovulation induction.The timing of HCG trigger mainly depends on follicular diameter, serum estrogen and endometrial situation during ovulation induction. HCG and GnRH-a can be used for triggering during ovulation induction. The reasonable choice of triggering-drugs should be made according to different patients and ovulation induction protocols，which will be great helpful to improve the outcomes and decrease the complications.

Key words: ovulation induction, human chorionic gonadotropin, timing of trigger

中图分类号:

R321-33

史潇，全松. 促排卵中人绒毛膜促性腺激素扳机时机与药物选择[J]. 中国实用妇科与产科杂志, DOI: 10.7504/fk2014120105.

SHI Xiao, QUAN Song.. Timing of HCG trigger and choice of triggering-drugs during ovulation induction.[J]. Acta Metallurgica Sinica, DOI: 10.7504/fk2014120105.

参考文献

[1］庄广伦. 现代辅助生殖技术［M］.北京：人民卫生出版社，2005：108-110.

[2］ Humaidan P, Alsbjerg B. GnRHa trigger for final oocyte maturation: is HCG trigger history? ［J］.Reprod Biomed Online，2014,29(3):274-280.

[3］ Conti M, Hsieh M, Musa ZA, et al. Novel signaling mechanisms in the ovary during oocyte maturation and ovulation［J］. Mol Cell Endocrinol, 2012 356(1-2):65-73.

[4］朱桂金,徐蓓,聂睿.促性腺激素峰的作用与人绒毛膜促性腺激素诱发排卵［J］.生殖医学杂志,2012,21(6):539-543.

[5］全松, 陈雷宁. 宫腔内人工授精与促排卵［M］.北京：人民卫生出版社，2011：78-89，140-150.

[6］ da Silva AL, Arbo E, Fanchin R.Early versus late HCG administration to trigger ovulation in mild stimulated IUI cycles: a randomized clinical trial［J］. Eur J Obstet Gynecol Reprod Biol, 2012, 164(2):156-160.

[7］ Shalom-Paz E, Marzal A, Wiser A, et al. Does optimal follicular size in IUI cycles vary between clomiphene citrate and gonadotrophins treatments?［J］. Gynecol Endocrinol,2014,30(2):107-110.

[8］ Jayaprakasan K, Hopkisson JF, Campbell BK, et al. Quantification of the effect of pituitary down-regulation on 3D ultrasound predictors of ovarian response ［J］. Hum Reprod, 2009, 23(7):1538-1544.

[9］崔艳国,全松,邢福祺，等.COH周期中卵泡径线大小与体外受精-胚胎移植妊娠率的相关性［J］.广东医学,2007,28(5):753-755.

[10］方媛媛,王秀霞. 人绒毛膜促性腺激素注射日卵泡大小与体外受精-胚胎移植妊娠率的关系［J］. 中国实用妇科与产科杂志,2010, 26(7):543-545.

[11］李艳辉,高颖,耿育红,等. 不同hCG日判定标准对IVF/ICSI-ET治疗结局的影响［J］. 国际生殖健康/计划生育杂志,2014,33(3):232-235.

[12］蔡素芬,张顺吉,龚斐. 控制性超促排卵中人绒毛膜促性腺激素最佳扳机时间的探讨［J］. 生殖与避孕,2012,32(9):607-612.

[13］ Wu Z, Li R, Ma Y, et al. Effect of HCG-day serum progesterone and oestradiol concentrations on pregnancy outcomes in GnRH agonist cycles［J］. Reprod Biomed Online, 2012,24(5):511-520.

[14］ Ta?kin EA, Atabekoälu CS, Musali N, et al. Association of serum estradiol levels on the day of hCG administration with pregnancy rates and embryo scores in fresh ICSI/ET cycles down regulated with either GnRH agonists or GnRH antagonists ［J］. Arch Gynecol Obstet, 2014,289(2):399-405.

[15］丁晨,赵淑芹. HCG日单个卵泡雌激素水平对IVF结局的影响［J］. 中国优生与遗传杂志,2012,20(11):108-110.

[16］ Orvieto R, Zohav E, Scharf S, et al. The influence of estradiol/follicle and estradiol/oocyte ratios on the outcome of controlled ovarian stimulation for in vitro fertilization［J］. Gynecol Endocrinol, 2007, 23(2):72-75.

[17］ Var T, Tonguc E, Dogan M, et al.Relationship between the oestradiol/oocyte ratio and the outcome of assisted reproductive technology cycles with gonadotropin releasing hormone agonist［J］. Gynecol Endocrinol, 2011,27(8):558-561.

[18］倪郝,陈雷宁,全松,等. 长方案垂体降调节行IVF-ET时雌二醇水平变化的意义［J］. 南方医科大学学报,2011,31(2):365-368.

[19］ Zhao J, Zhang Q, Li Y. The effect of endometrial thickness and pattern measured by ultrasonography on pregnancy outcomes during IVF-ET cycles［J］. Reprod Biol Endocrinol, 2012, 100 (1):1-6.

[20］ Zhao J, Zhang Q, Wang Y, et al. Endometrial pattern, thickness and growth in predicting pregnancy outcome following 3319 IVF cycle［J］. Reprod Biomed Online, 2014, 29(3): 291-298.

[21］ Lamanna G, Scioscia M, Lorusso F,et al. Parabolic trend in endometrial thickness at embryo transfer in in vitro fertilization/intracytoplasmic sperm injection cases with clinical pregnancy evidence［J］. Fertil Steril, 2008, 90(4):1272-1274.

[22］ Xu B, Li Z, Zhang H, et al. Serum progesterone level effects on the outcome of in vitro fertilization in patients with differentovarian response: analysis of more than 10,000 cycles［J］. Fertil Steril, 2012,97(6):1321-1327.

[23］ Youssef MA, Al-Inany HG, Aboulghar M, et al. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles［J］. Cochrane Database Syst Rev, 2011, 13(4):CD003719.

[24］ Madani T, Mohammadi YL, et al. Comparing the efficacy of urinary and recombinant hCG on oocyte/follicle ratio to trigger ovulation in women undergoing intracytoplasmic sperm injection cycles: a randomized controlled trial［J］. J Assist Reprod Genet, 2013, 30(2):239-245.

[25］ Humaidan P, Kol S, Papanikolaou EG, et al. GnRH agonist for triggering of final oocyte maturation: time for a change of practice?［J］. Hum Reprod Update, 2011, 17(4):510-524.

[26］ Castillo JC, Humaidan P, Bernabéu R. Pharmaceutical options for triggering of final oocyte maturation in ART［J］. Biomed Res Int, 2014，2014:580171.

[27］ Lin MH, Wu FS, Lee RK, et al. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles［J］. Fertil Steril, 2013,100(5):1296-1302.

[28］ Griffin D, Benadiva C, Kummer N, et al. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders［J］. Fertil Steril, 2012, 97(6):1316-1320.

[1]	黄晨阳, 孙海翔. 妇科恶性肿瘤患者促排卵及胚胎移植方案的选择[J]. 中国实用妇科与产科杂志, 2022, 38(6): 614-618.
[2]	黄珈. 黄体期促排卵的利弊分析[J]. 中国实用妇科与产科杂志, 2021, 37(4): 435-440.
[3]	陈春林，孟凡良. 输卵管妊娠诊治过程中应该重视的问题[J]. 中国实用妇科与产科杂志, 2019, 35(1): 59-64.
[4]	张学红，王丽艳. 早发性卵巢功能不全促生育治疗[J]. 中国实用妇科与产科杂志, 2018, 34(3): 258-261.
[5]	王玉东，周赟. 早期异位妊娠快速诊断新方法[J]. 中国实用妇科与产科杂志, 2017, 33(9): 881-884.
[6]	孙伟. 中医药在促排卵中的应用[J]. 中国实用妇科与产科杂志, 2015, 31(1): 50-52.
[7]	乔杰，张曜耀，李蓉. 重视促排卵的质量与安全性[J]. 中国实用妇科与产科杂志, 2015, 31(1): 13-14.
[8]	刘冬娥. 促排卵周期中的黄体支持[J]. 中国实用妇科与产科杂志, 2015, 31(1): 35-38.
[9]	邵小光. 人工授精周期中诱发排卵方法选择[J]. 中国实用妇科与产科杂志, 2015, 31(1): 43-46.
[10]	马彩虹，王洋. 促排卵并发症及其防治[J]. 中国实用妇科与产科杂志, 2015, 31(1): 39-43.
[11]	左娜，王秀霞. 促排卵治疗的母儿安全性[J]. 中国实用妇科与产科杂志, 2015, 31(1): 46-50.
[12]	孙伟. 中医药在促排卵中的应用[J]. 中国实用妇科与产科杂志, 2015, 31(1): 41-44.
[13]	王光演，牛志宏，孙贻娟，冯云. 依据扳机日血清E2值制定HCG剂量对ICSI结局的影响[J]. 中国实用妇科与产科杂志, 2014, 30(8): 615-618.
[14]	艾继辉，赵义清，朱桂金. 多囊卵巢综合征不孕妇女助孕时机与助孕方式选择[J]. 中国实用妇科与产科杂志, 2013, 9(11): 874-878.